Zenas BioPharma (ZBIO) Income from Continuing Operations (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Income from Continuing Operations of 80987000.0 for Q1 2026, down 141.23% year-over-year from 196443649.38 in Q1 2025, and up 67.75% quarter-over-quarter from 251135000.0 in Q4 2025.
Zenas BioPharma (ZBIO) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Zenas BioPharma's Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 80987000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 141.23% year-over-year to 80987000.0; the TTM figure through Mar 2026 stood at 435844000.0 (down 168.49% YoY), while the FY2025 annual figure was 388430000.0, down 147.43% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 80987000.0, up from 251135000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 35624000.0 in Q3 2023, with the low at 251135000.0 in Q4 2025.
- The 4-year median for Income from Continuing Operations is 38606000.0 (2024), against an average of 55970909.09.
- Peak annual rise in Income from Continuing Operations reached 20.77% in 2025, while the deepest fall reached 381.33% in 2025.
- Zenas BioPharma's Income from Continuing Operations stood at 25329000.0 in 2023, then plunged by 105.99% to 52175000.0 in 2024, then plunged by 381.33% to 251135000.0 in 2025, then surged by 67.75% to 80987000.0 in 2026.
- Business Quant data shows ZBIO's Income from Continuing Operations at 80987000.0 in Q1 2026, 251135000.0 in Q4 2025, and 51499000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | -111.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -111.46 Mn |
| Mar 31, 2026 | -80.99 Mn |
| Dec 31, 2025 | -251.14 Mn |
| Sep 30, 2025 | -51.50 Mn |
| Jun 30, 2025 | -52.22 Mn |
| Mar 31, 2025 | -33.57 Mn |
| Dec 31, 2024 | -52.18 Mn |
| Sep 30, 2024 | -38.61 Mn |
| Jun 30, 2024 | -37.98 Mn |
| Mar 31, 2024 | -27.80 Mn |
| Dec 31, 2023 | -25.33 Mn |
| Sep 30, 2023 | 35.62 Mn |